2026-06-16

Cocoa bull 9.0% vs prior close ($3,882.00 → $4,232.00)

Platinum volume spike - 8.7× the 20-day average (110 vs 12 avg)

WTI Crude Oil bear 6.1% vs prior close ($80.75 → $75.83)

OSINT: BMW reporting alert raises concerns for German auto sector

Oil -5.55% - significant selloff

OSINT: UK Defense Spending Cuts Threaten Military Procurement

Oil -4.66% - significant selloff

OSINT: Iranian FM says US-Iran final agreement talks likely to begin Friday

OSINT: US Oil Reserves Drop to 43-Year Low Amid Trump Price-Control Push

Cotton bull 5.9% vs prior close ($73.43 → $77.76)

Sugar No. 11 bull 4.5% vs prior close ($13.68 → $14.29)

Coffee bull 4.1% vs prior close ($262.95 → $273.60)

Silver volume spike - 2.2× the 20-day average (255 vs 115 avg)

Gold +1.11% - significant rally

NATURAL GAS - speculators net long (+2.3σ vs 52w mean) - contrarian bear signal

Oil -2.79% - significant selloff

OSINT: UK Announces New Sanctions Targeting Russian Entities

RBOB Gasoline bear 3.9% vs prior close ($2.95 → $2.83)

Heating Oil bear 3.3% vs prior close ($3.27 → $3.16)

Natural Gas bull 3.4% vs prior close ($3.15 → $3.26)

FDA approves SPINRAZA (BIOGEN) - new revenue stream

FDA approves SPINRAZA (BIOGEN) - new revenue stream

FDA approves SPINRAZA (BIOGEN) - new revenue stream

FDA approves KALETRA (AbbVie) - new revenue stream

FDA approves KALETRA (AbbVie) - new revenue stream

FDA approves KALETRA (AbbVie) - new revenue stream

Phase 3 trial terminated early - JOHNSON A Study of Cisapride in Premature Infants With Feeding Problems

Phase 3 trial terminated early - JOHNSON A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the T

Phase 3 trial terminated early - JOHNSON Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment

Phase 3 trial terminated early - ELI A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Phase 3 trial terminated early - ELI A Study of Baricitinib (LY3009104) in Children With COVID-19

Phase 3 trial terminated early - ELI Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADH

Phase 3 trial terminated early - ELI Duloxetine for the Treatment of Chronic Pelvic Pain

Phase 3 trial terminated early - ELI A Long-Term Study in Schizophrenia

Phase 3 trial terminated early - BRISTOL A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Phase 3 trial terminated early - BRISTOL A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pe

FDA approves SOTYKTU (BRISTOL) - new revenue stream

Phase 3 trial terminated early - BIOGEN Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosi

Phase 3 trial terminated early - BIOGEN A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants

Phase 3 trial terminated early - BIOGEN 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase 3 trial terminated early - BIOGEN BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sc

Phase 3 trial terminated early - AMGEN A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as

Phase 3 trial terminated early - AMGEN STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Ou

Phase 3 trial terminated early - INCYTE The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adu

Phase 3 trial terminated early - INCYTE A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopi

Phase 3 trial terminated early - Medtronic BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Ther

Phase 3 trial terminated early - AbbVie Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natal

Phase 3 trial terminated early - Merck Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non

Phase 3 trial terminated early - Merck Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyper

Phase 3 trial terminated early - Merck An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Coliti

Phase 3 trial terminated early - PFIZER Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients

Phase 3 trial terminated early - PFIZER An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Rena

Phase 3 trial terminated early - PFIZER Extension Study Of Tanezumab In Osteoarthritis

Phase 3 trial terminated early - PFIZER Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With

Phase 3 trial terminated early - PFIZER Renal Allograft Function and Histology Following Switching From A Tacrolimus to

Phase 3 trial terminated early - PFIZER Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-P

Phase 3 trial terminated early - PFIZER Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Di

Phase 3 trial terminated early - ABBOTT The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cart

Phase 3 trial terminated early - ABBOTT LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Phase 3 trial terminated early - ABBOTT Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

Phase 3 trial terminated early - GILEAD Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of

Phase 3 trial terminated early - GILEAD Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Act

Phase 3 trial terminated early - GILEAD DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Stud

Phase 3 trial terminated early - GILEAD Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (

Phase 3 trial terminated early - GILEAD Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced C

Phase 3 trial terminated early - GILEAD Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidin

Phase 3 trial terminated early - GILEAD Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardiovers

GE Vernova Inc. search volume spiked +100 pts - unusual interest

LINDE PLC search volume spiked +100 pts - unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

5 congress members traded TSCO - net BEAR (0B/0S)

Beat consensus by 28.4% - EPS $0.33 vs $0.257 estimate

Beat consensus by 7.6% - EPS $0.31 vs $0.288 estimate

Q1-2026: Beat consensus by 21.1% - EPS $0.38 vs $0.3138 estimate

Q2-2020: Beat consensus by 15.3% - EPS $-0.19 vs $-0.2244 estimate

Q4-2017: Missed consensus by 48.0% - EPS $0.16587 vs $0.3188 estimate

Q2-2025: Beat consensus by 33.3% - EPS $-0.34 vs $-0.5101 estimate

Q4-2025: Missed consensus by 61.8% - EPS $-1.35 vs $-0.8343 estimate

Missed consensus by 12.7% - EPS $-0.46 vs $-0.408 estimate

Beat consensus by 34.8% - EPS $-0.66 vs $-1.012 estimate

Beat consensus by 32.6% - EPS $-55 vs $-81.6 estimate

Beat consensus by 24.6% - EPS $-50 vs $-66.3 estimate

Beat consensus by 91.5% - EPS $-4 vs $-46.92 estimate

Missed consensus by 28.2% - EPS $-34 vs $-26.52 estimate

Q1-2024: Beat consensus by 23.0% - EPS $-0.07 vs $-0.0909 estimate

Q4-2023: Missed consensus by 1665.7% - EPS $-1.07 vs $-0.0606 estimate

Q3-2024: Missed consensus by 44.0% - EPS $-0.16 vs $-0.1111 estimate

Missed consensus by 325.7% - EPS $-0.43 vs $-0.101 estimate

Q4-2025: Beat consensus by 5.6% - EPS $2.8 vs $2.6513 estimate

Q3-2025: Missed consensus by 124.1% - EPS $-0.16 vs $-0.0714 estimate

Q4-2025: Missed consensus by 102.3% - EPS $-0.002 vs $0.0867 estimate

Q1-2026: Missed consensus by 41.3% - EPS $-0.49 vs $-0.3468 estimate

Missed consensus by 42.9% - EPS $-0.51 vs $-0.357 estimate

Q1-2026: Missed consensus by 432.2% - EPS $-0.38 vs $-0.0714 estimate

Q3-2025: Beat consensus by 19.3% - EPS $-0.07 vs $-0.0867 estimate

Q1-2026: Missed consensus by 936.4% - EPS $-0.74 vs $-0.0714 estimate

Q2-2025: Beat consensus by 149.0% - EPS $0.04 vs $-0.0816 estimate

Q3-2025: Beat consensus by 95.5% - EPS $-0.01 vs $-0.2244 estimate

Beat consensus by 28.1% - EPS $-0.11 vs $-0.153 estimate

Q2-2025: Beat consensus by 34.6% - EPS $-0.04 vs $-0.0612 estimate

Missed consensus by 8.1% - EPS $-0.08 vs $-0.074 estimate

Q3-2025: Missed consensus by 52.5% - EPS $-1.75 vs $-1.1475 estimate

Missed consensus by 56.9% - EPS $-2 vs $-1.275 estimate

Beat consensus by 26.5% - EPS $-0.75 vs $-1.02 estimate

Q4-2025: Beat consensus by 72.0% - EPS $-0.25 vs $-0.8925 estimate

Q1-2026: Beat consensus by 8.6% - EPS $1.08 vs $0.9949 estimate

Q4-2025: Beat consensus by 14.2% - EPS $1.16 vs $1.0161 estimate

Q2-2026: Beat consensus by 13.1% - EPS $1.18 vs $1.0437 estimate

Q3-2026: Beat consensus by 7.4% - EPS $1.25 vs $1.1644 estimate

Missed consensus by 6.0% - EPS $3.12 vs $3.32 estimate

Q2-2024: Beat consensus by 10.1% - EPS $3.28 vs $2.9801 estimate

Q4-2025: Beat consensus by 26.7% - EPS $-0.05 vs $-0.0682 estimate

Q1-2026: Beat consensus by 57.6% - EPS $-0.03 vs $-0.0707 estimate

Q2-2025: Missed consensus by 13.2% - EPS $-0.11 vs $-0.0972 estimate

Q1-2026: Beat consensus by 15.3% - EPS $0.6 vs $0.5202 estimate

Q4-2025: Missed consensus by 8.4% - EPS $0.65 vs $0.7095 estimate

Q2-2025: Missed consensus by 23.2% - EPS $0.57 vs $0.7423 estimate

Beat consensus by 67.3% - EPS $-4.75 vs $-14.535 estimate

Beat consensus by 26.5% - EPS $-14.25 vs $-19.38 estimate

Q4-2025: Missed consensus by 47.9% - EPS $-1.44 vs $-0.9737 estimate

Q1-2026: Missed consensus by 52.5% - EPS $-0.57 vs $-0.3737 estimate

Q2-2025: Beat consensus by 54.5% - EPS $-3.67632 vs $-8.0719 estimate

Q3-2025: Missed consensus by 59.4% - EPS $-1.56843 vs $-0.9838 estimate

Q1-2019: Beat consensus by 1210.7% - EPS $2.16 vs $0.1648 estimate

Q4-2019: Missed consensus by 348.8% - EPS $-3.28 vs $1.3184 estimate

Q4-2018: Beat consensus by 252.6% - EPS $1.76 vs $-1.1536 estimate

Sanofi search volume spiked +77 pts - unusual interest

Strategy Inc search volume spiked +26 pts - unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

5 congress members traded TSCO - net BEAR (0B/0S)

Sanofi search volume spiked +77 pts - unusual interest

Q4-2025: Beat consensus by 26.8% - EPS $2.02 vs $1.5926 estimate

Missed consensus by 12.0% - EPS $1.63 vs $1.852 estimate

Q2-2025: Beat consensus by 10.4% - EPS $1.6 vs $1.4499 estimate

Q3-2025: Beat consensus by 57.3% - EPS $3.09 vs $1.9642 estimate

Q3-2025: Beat consensus by 207.7% - EPS $0.18 vs $0.0585 estimate

Q1-2026: Missed consensus by 28.8% - EPS $0.13 vs $0.1826 estimate

Beat consensus by 23.8% - EPS $25.25417 vs $20.402 estimate

Q3-2026: Beat consensus by 25.9% - EPS $40.57406 vs $32.2291 estimate

Q4-2026: Beat consensus by 49.7% - EPS $41.327 vs $27.6013 estimate

Bond issued at elevated rate 4.7% - credit-stress signal

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

5 congress members traded TSCO - net BEAR (0B/0S)

Sanofi search volume spiked +77 pts - unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

5 congress members traded TSCO - net BEAR (0B/0S)

OSINT: Marathon Digital (MARA) buys 1,000 BTC after selling 20,880 BTC in Q1 2026

OSINT: Elon Musk's Net Worth Jumps $165B to $1.3 Trillion, Surpassing Gates

OSINT: SpaceX IPO price discovery shifts to crypto exchanges, Binance leads volume

OSINT: Gov. Newsom alleges Trump ordered DOJ probe into him

Q2-2025: EPS $0.06 vs $0.0273 estimate, +0.03 on a near-zero consensus

Q4-2018: EPS $-0.0032 vs $0.0417 estimate, -0.04 on a near-zero consensus

Q4-2025: EPS $-0.05 vs $-0.0255 estimate, -0.02 on a near-zero consensus

Q3-2025: EPS $0.00 vs $-0.0179 estimate, +0.02 on a near-zero consensus

Q2-2025: EPS $0.00 vs $-0.0204 estimate, +0.02 on a near-zero consensus

Q1-2025: EPS $-0.05 vs $-0.0255 estimate, -0.02 on a near-zero consensus

Q3-2025: EPS $-0.07 vs $0.0204 estimate, -0.09 on a near-zero consensus

Q1-2025: EPS $-0.09 vs $-0.0255 estimate, -0.06 on a near-zero consensus

Q1-2026: EPS $-0.04 vs $-0.0204 estimate, -0.02 on a near-zero consensus

Q2-2025: EPS $0.02 vs $-0.0136 estimate, +0.03 on a near-zero consensus

Q1-2026: EPS $-0.01 vs $-0.0204 estimate, +0.01 on a near-zero consensus

Q4-2025: EPS $-0.02 vs $-0.0255 estimate, +0.01 on a near-zero consensus

Q1-2025: EPS $-0.27 vs $-0.0408 estimate, -0.23 on a near-zero consensus

Q4-2024: EPS $-0.17 vs $0.0204 estimate, -0.19 on a near-zero consensus

EPS $-0.03 vs $-0.017 estimate, -0.01 on a near-zero consensus

Q3-2025: EPS $0.01 vs $0.0034 estimate, +0.01 on a near-zero consensus

Q4-2026: EPS $0.04 vs $-0.0061 estimate, +0.05 on a near-zero consensus

Q2-2026: EPS $-0.03 vs $0.0082 estimate, -0.04 on a near-zero consensus

Q3-2026: EPS $0.02 vs $0.0068 estimate, +0.01 on a near-zero consensus

Q1-2026: EPS $-0.08 vs $-0.0102 estimate, -0.07 on a near-zero consensus

EPS $-0.39 vs $0.047 estimate, -0.44 on a near-zero consensus

BTC ETF outflow of $3013M - institutional selling

ETH ETF outflow of $784M - institutional selling

SOL open interest -32.0% - OI collapse

ETH open interest -66.5% - OI collapse

BTC open interest -40.8% - OI collapse

BTC open interest -39.9% - OI collapse

SOL open interest +292.8% - OI surge

ETH open interest +216.8% - OI surge

SPYx/USDC has $31.0M volume but only $578K liquidity - thin market, slippage risk

ETH open interest +211.8% - OI surge

SOL open interest +293.7% - OI surge

BTC open interest +233.8% - OI surge

BITCOIN - speculators net long (+2.5σ vs 52w mean) - contrarian bear signal

ETH DEX volume/liquidity ratio elevated (0.59x) - strong on-chain trading activity

SOL DEX volume/liquidity ratio elevated (0.84x) - strong on-chain trading activity

ETH DEX volume/liquidity ratio elevated (0.58x) - strong on-chain trading activity

OSINT: Marathon Digital (MARA) buys 1,000 BTC after selling 20,880 BTC in Q1 2026

OSINT: DeFi Exploits Trigger $13B Outflows, On‑chain Leverage Hits 2021 Levels

OSINT: Crypto Whale Wins $4.2M Bet on Spain‑Cabo Verde Draw, Raises Insider‑Info Concer

OSINT: Elon Musk's Net Worth Jumps $165B to $1.3 Trillion, Surpassing Gates

OSINT: SpaceX IPO price discovery shifts to crypto exchanges, Binance leads volume

SOL DEX volume/liquidity ratio elevated (0.95x) - strong on-chain trading activity

OSINT: Gov. Newsom alleges Trump ordered DOJ probe into him

OSINT: UK Announces New Sanctions Targeting Russian Entities

Financial conditions loosening - NFCI at -0.51, liquidity supportive

OSINT: Gov. Newsom alleges Trump ordered DOJ probe into him

OSINT: UK Announces New Sanctions Targeting Russian Entities

OSINT: Elon Musk's Net Worth Jumps $165B to $1.3 Trillion, Surpassing Gates

OSINT: Gov. Newsom alleges Trump ordered DOJ probe into him